Swedish Orphan Biovitrum
SOBI | ST
Overview
Corporate Details
- ISIN(s):
- SE0000872095 (+51 more)
- LEI:
- 549300124Y3MQI87PT35
- Country:
- Sweden
- Address:
- Tomtebodavagen 23A, 112 76 Stockholm
- Website:
- https://www.sobi.com/en
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care. - Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care - Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia - A and B respectively in several markets - A strong portfolio of on-market products, and an extensive portfolio of pre-market assets - An international biopharmaceutical company covering the entire value chain - We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Swedish Orphan Biovitrum.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-16 08:00 |
Quarterly Report
|
Swedish | 4.1 MB | |
| 2025-07-16 08:00 |
Earnings Release
|
English | 4.1 MB | |
| 2025-07-15 19:15 |
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
|
English | 138.4 KB | |
| 2025-07-15 19:15 |
Transaction in Own Shares
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åt…
|
Swedish | 137.1 KB | |
| 2025-07-01 13:00 |
M&A Activity
Sobi uppdaterar avtalet med Apellis om royalty på Aspaveli® (systemisk pegcetac…
|
Swedish | 193.0 KB | |
| 2025-07-01 13:00 |
M&A Activity
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli…
|
English | 202.6 KB | |
| 2025-06-28 00:55 |
Regulatory News Service
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…
|
English | 227.3 KB | |
| 2025-06-28 00:55 |
Earnings Release
FDA godkänner Gamifant® (emapalumab-lzsg) som den första behandlingen för vuxna…
|
Swedish | 244.4 KB | |
| 2025-05-08 11:30 |
Post-Annual General Meeting Information
Kommuniké från Sobis årsstämma
|
Swedish | 148.7 KB | |
| 2025-05-08 11:30 |
Post-Annual General Meeting Information
Bulletin from Sobi’s Annual General Meeting (AGM)
|
English | 158.7 KB | |
| 2025-04-29 08:00 |
Quarterly Report
|
Swedish | 4.1 MB | |
| 2025-04-29 08:00 |
Quarterly Report
|
English | 4.1 MB | |
| 2025-02-05 08:01 |
Earnings Release
|
Swedish | 4.1 MB | |
| 2025-02-05 08:01 |
Earnings Release
|
English | 4.0 MB | |
| 2025-01-10 18:00 |
Earnings Release
Sobis intäkter för helåret 2024 högre än tidigare uppskattningar
|
Swedish | 144.9 KB |
Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-15 | Bo Jesper Hansen | Other | Buy | 267 | 63,706.20 SEK |
| 2023-05-15 | Bo Jesper Hansen | Other | Buy | 199 | 47,401.80 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 11,207 | 2,614,705.17 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 5,936 | 1,383,978.40 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 2,546 | 595,560.32 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 1,026 | 238,524.48 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 839 | 197,215.34 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 679 | 158,886.00 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 500 | 117,400.00 SEK |
| 2023-05-12 | Bo Jesper Hansen | Other | Buy | 410 | 95,571.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |